Skip to main content
Equibles
ALXO logo

ALXO · Alx Oncology Holdings Inc

Track ALXO — free

Use ALXO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ALXO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.96 +0.02 (+1.03%) At close · Aug 14
Market Cap
$271.02M
Shares
138.28M

Alx Oncology Holdings Inc Earnings Call Transcripts

Every quarterly earnings call for Alx Oncology Holdings Inc (ALXO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-08
Alx Oncology Holdings Inc Q1 FY2026 Earnings Call
Confident tone EVO + zanidatumab HER2-positive breast cancer data (ESMO) CD47 biomarker predictive value ALX 2004 EGFR-targeted ADC program
Diluted EPS
$-0.17
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-27
Alx Oncology Holdings Inc Q4 FY2025 Earnings Call
Confident tone CD47 biomarker validation across HER2-positive tumors Phase II ASPEN-09 breast cancer trial ALX 2004 EGFR ADC dose escalation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-07
Alx Oncology Holdings Inc Q3 FY2025 Earnings Call
Confident tone Avorpicept development strategy / targeted IO positioning ASPEN-06 / CD47 biomarker data in gastric cancer ALX2004 EGFR-targeted ADC
Diluted EPS
$-0.41
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Alx Oncology Holdings Inc Q2 FY2025 Earnings Call
Confident tone CD47 as predictive biomarker for evorpacept ASPEN-06 trial data and response rates Breast cancer program redesign
Diluted EPS
$-0.49
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Alx Oncology Holdings Inc Q1 FY2025 Earnings Call
Diluted EPS
$-0.58
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Alx Oncology Holdings Inc Q4 FY2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Alx Oncology Holdings Inc Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 earnings calls
Key facts CIK 1810182 CUSIP 00166B105 13F (30d) 95 filings 94 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)